These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Recent progress in development of antibiotics against Gram-negative bacteria]. Xu ZQ; Xu ZY Yao Xue Xue Bao; 2013 Jul; 48(7):993-1004. PubMed ID: 24133966 [TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
7. Developments on antibiotics for multidrug resistant bacterial Gram-negative infections. Voulgaris GL; Voulgari ML; Falagas ME Expert Rev Anti Infect Ther; 2019 Jun; 17(6):387-401. PubMed ID: 31006284 [No Abstract] [Full Text] [Related]
8. Will new antimicrobials overcome resistance among Gram-negatives? Bassetti M; Ginocchio F; Mikulska M; Taramasso L; Giacobbe DR Expert Rev Anti Infect Ther; 2011 Oct; 9(10):909-22. PubMed ID: 21973303 [TBL] [Abstract][Full Text] [Related]
9. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens. Cornaglia G; Rossolini GM Clin Microbiol Infect; 2009 Mar; 15(3):218-23. PubMed ID: 19335369 [TBL] [Abstract][Full Text] [Related]
10. Metalloenzyme inhibitors for the treatment of Gram-negative bacterial infections: a patent review (2009-2012). Supuran CT; Carta F; Scozzafava A Expert Opin Ther Pat; 2013 Jul; 23(7):777-88. PubMed ID: 23458841 [TBL] [Abstract][Full Text] [Related]
11. What is in the pipeline for Gram-negative pathogens? Talbot GH Expert Rev Anti Infect Ther; 2008 Feb; 6(1):39-49. PubMed ID: 18251663 [TBL] [Abstract][Full Text] [Related]
12. Understanding efflux in Gram-negative bacteria: opportunities for drug discovery. Schweizer HP Expert Opin Drug Discov; 2012 Jul; 7(7):633-42. PubMed ID: 22607346 [TBL] [Abstract][Full Text] [Related]
13. Multidrug efflux pumps and their role in antibiotic and antiseptic resistance: a pharmacodynamic perspective. Alibert S; N'gompaza Diarra J; Hernandez J; Stutzmann A; Fouad M; Boyer G; Pagès JM Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):301-309. PubMed ID: 27764576 [TBL] [Abstract][Full Text] [Related]
14. Multidrug-resistant gram-negative infections. Bringing back the old. Chan-Tompkins NH Crit Care Nurs Q; 2011; 34(2):87-100. PubMed ID: 21407003 [TBL] [Abstract][Full Text] [Related]
15. Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Giamarellou H Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S50-4. PubMed ID: 21129924 [TBL] [Abstract][Full Text] [Related]
17. Trends in multidrug-resistant gram-negative bacilli and the role of prolonged β-lactam infusion in the intensive care unit. Guervil DJ; Chau T Crit Care Nurs Q; 2013; 36(4):345-55. PubMed ID: 24002425 [TBL] [Abstract][Full Text] [Related]
18. Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use. Lomovskaya O; Bostian KA Biochem Pharmacol; 2006 Mar; 71(7):910-8. PubMed ID: 16427026 [TBL] [Abstract][Full Text] [Related]
19. [Clinical assessment of colistin in treating infections caused by multidrug-resistant gram-negative bacillus in patients with severe burn]. Zhang JP; Yang XS; Chen J; Peng YZ; Huang YS Zhonghua Shao Shang Za Zhi; 2009 Oct; 25(5):372-6. PubMed ID: 19951562 [TBL] [Abstract][Full Text] [Related]
20. Overcoming multidrug resistance in gram-negative bacteria. Poole K Curr Opin Investig Drugs; 2003 Feb; 4(2):128-39. PubMed ID: 12669372 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]